AnHorn Medicines announced in Taipei that its lead neuroprotective candidate AH-008 has received Investigational New Drug clearance from the U.S. Food and Drug Administration and Index Case designation from the Taiwan Center for Drug Evaluation.
AH-008 is being developed to prevent chemotherapy-induced peripheral neuropathy, a common and dose-limiting toxicity of treatments such as taxanes, platinum-based agents, vinca alkaloids and antibody-drug conjugates that can cause irreversible nerve damage and long-term impairment.
The FDA IND clearance authorizes AH-008 to advance into human clinical trials, while the Taiwan CDE Index Case designation recognizes the program as a reference for novel drug development in its category. According to the company, preclinical studies were designed in accordance with the FDA draft guidance issued in January 2025. They demonstrated robust neuroprotective effects across multiple chemotherapy-induced neuropathy models without compromising chemotherapy efficacy.
According to the company, AnHorn advanced the AH-008 from the preclinical stage to FDA IND clearance in 12 months, a timeline it cites as evidence of its integrated translational and CMC capabilities and a step toward clinical evaluation of a first-in-class preventive therapy for CIPN.
